Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
10 4월 2024 - 8:30PM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three
Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM,
(
Safety,
Efficacy, and
Quantitative
Understanding of
Obstruction
Impact of
Aficamten in
HCM), the pivotal
Phase 3 clinical trial of aficamten in patients with
symptomatic obstructive hypertrophic cardiomyopathy (HCM), at Heart
Failure 2024, an International Congress of the European Society of
Cardiology, taking place in Lisbon, Portugal from May 11, 2024 –
May 14, 2024.
Title: Aficamten for the
Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy:
SEQUOIA-HCM an International Multicenter Phase 3
TrialPresenter: Martin Maron, M.D., Director,
Hypertrophic Cardiomyopathy Center, Lahey Hospital and Medical
CenterDate: May 13, 2024Topic:
Heart Failure AssociationSession Title: Late
Breaking Clinical Trials: LVAD, HFpEF and Hypertrophic
CardiomyopathySession Type: Late Breaking
ScienceSession Time: 1:45-2:45 PM
WESTPresentation Time: 2:09 PM
WESTLocation: Room 1
Title: Enhancing Exercise
Response in Obstructive HCM: Insights from Aficamten's Impact on
Patients with Obstructive Hypertrophic Cardiomyopathy in
SEQUOIA-HCM Presenter: Gregory Lewis, M.D.,
Jeffrey and Mary Ellen Jay Chair and Section Head, Heart Failure
Medical Director, Cardiopulmonary Exercise Testing Laboratory,
Professor of Medicine, Harvard Medical SchoolDate:
May 13, 2024Topic: Heart Failure
AssociationSession Title: Late Breaking Clinical
Trials: LVAD, HFpEF and Hypertrophic CardiomyopathySession
Type: Late Breaking ScienceSession Time:
1:45-2:45 PM WESTPresentation Time: 2:21 PM
WESTLocation: Room 1
Title: Dosing and Safety
Profile of Aficamten in Symptomatic Obstructive Hypertrophic
Cardiomyopathy: Results from SEQUOIA-HCMPresenter:
Caroline Coats, M.D., Ph.D., Lead Clinician, West of Scotland
Inherited Cardiac Conditions Service, Honorary Senior Lecturer,
School of Cardiovascular and Metabolic Health, University of
GlasgowDate: May 13, 2024Topic:
Heart Failure AssociationSession Title: Late
Breaking Clinical Trials: LVAD, HFpEF and Hypertrophic
CardiomyopathySession Type: Late Breaking
ScienceSession Time: 1:45-2:45 PM
WESTPresentation Time: 2:33 PM
WESTLocation: Room 1
About Cytokinetics
Cytokinetics is a late-stage, specialty
cardiovascular biopharmaceutical company focused on discovering,
developing and commercializing first-in-class muscle activators and
next-in-class muscle inhibitors as potential treatments for
debilitating diseases in which cardiac muscle performance is
compromised. As a leader in muscle biology and the mechanics of
muscle performance, the company is developing small molecule drug
candidates specifically engineered to impact myocardial muscle
function and contractility. Cytokinetics is preparing for
regulatory submissions for aficamten, its next-in-class cardiac
myosin inhibitor, following positive results from SEQUOIA-HCM, the
pivotal Phase 3 clinical trial in obstructive hypertrophic
cardiomyopathy. Aficamten is also currently being evaluated in two
ongoing Phase 3 clinical trials: MAPLE-HCM, evaluating aficamten as
monotherapy compared to metoprolol as monotherapy in patients with
obstructive HCM and ACACIA-HCM, evaluating aficamten in patients
with non-obstructive HCM. Cytokinetics is also developing omecamtiv
mecarbil, a cardiac muscle activator, in patients with heart
failure. Additionally, Cytokinetics is developing CK-586, a cardiac
myosin inhibitor with a mechanism of action distinct from aficamten
for the potential treatment of HFpEF, and CK-136, a cardiac
troponin activator for the potential treatment HFrEF and other
types of heart failure, such as right ventricular failure resulting
from impaired cardiac contractility.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to any of our other clinical
trials, statements relating to the potential benefits of omecamtiv
mecarbil, aficamten, or any of our other drug candidates.
Cytokinetics' research and development activities; the design,
timing, results, significance and utility of preclinical and
clinical results; and the properties and potential benefits of
Cytokinetics' other drug candidates. Such statements are based on
management's current expectations, but actual results may differ
materially due to various risks and uncertainties, including, but
not limited to, potential difficulties or delays in the
development, testing, regulatory approvals for trial commencement,
progression or product sale or manufacturing, or production of
Cytokinetics' drug candidates that could slow or prevent clinical
development or product approval; Cytokinetics' drug candidates may
have adverse side effects or inadequate therapeutic efficacy; the
FDA or foreign regulatory agencies may delay or limit Cytokinetics'
ability to conduct clinical trials; Cytokinetics may be unable to
obtain or maintain patent or trade secret protection for its
intellectual property; standards of care may change, rendering
Cytokinetics' drug candidates obsolete; and competitive products or
alternative therapies may be developed by others for the treatment
of indications Cytokinetics' drug candidates and potential drug
candidates may target. For further information regarding these and
other risks related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities and Exchange
Commission.
CYTOKINETICS® and the CYTOKINETICS and C-shaped
logo are registered trademarks of Cytokinetics in the U.S. and
certain other countries.
Contact:Cytokinetics Diane WeiserSenior Vice President,
Corporate Affairs(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Cytokinetics (NASDAQ:CYTK)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024